ArticleGeneral thoracic and cardiovascular surgery2026
Analysis of prognostic factors after pulmonary resection for metastatic breast cancer: a 23-year single-institution retrospective study.
Article in General thoracic and cardiovascular surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesRecent advances in therapeutics have substantially improved breast cancer treatment outcomes. However, data on prognostic factors after surgical resection of pulmonary metastases from breast cancer remain limited.
methodsThis single-center retrospective study analyzed data from patients with breast cancer who had undergone pulmonary metastasectomy between 2000 and 2023. We reviewed clinical and pathological parameters, including the disease-free interval (DFI), size and number of pulmonary metastases.
resultsThis study included 33 patients. The median postoperative survival of breast cancer patients with lung metastasis was 40 (range 4-217) months. According to univariate analysis, hormone receptor-positive breast cancer, pStage I or II breast cancer, lung metastases < 20 mm, hormone receptor-positive lung metastases, absence of other metastases, and DFI ≥ 24 months were significantly associated with better survival. Multivariate analysis identified DFI < 24 months (hazard ratio [HR] 9.520, 95% confidence interval [CI] 2.158-27.070) and tumor size ≥ 20 mm (HR 4.958, 95% CI 1.290-27.550) independently predicted poorer survival; ≥ 2 metastatic lesions showed a non-significant trend toward worse outcomes (HR 3.272, 95% CI 0.913-11.090).
conclusionsThis study clarified the criteria for pulmonary metastasectomy in patients with breast cancer. Considering subtype changes between the primary tumor and metastases could enable personalized therapies.
Indexed as
Identifiers
41099923What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.